Compare BioNTech SE - ADR (BNTX) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs National Beverage Corp. — how do they compare? BioNTech SE - ADR trades at $89.79 (market cap $22.86B), while National Beverage Corp. trades at $31.41 (market cap $2.89B). The key difference: BioNTech SE - ADR is far larger — about 7.9× National Beverage Corp.'s market cap, and BioNTech SE - ADR is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| BNTX | FIZZ | |
|---|---|---|
Market Cap | $22.86B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $47.69 |
52-Week Low | $83.89 | $30.92 |
Enterprise Value | $6.53B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
FIZZ (National Beverage Corp.) trades at $31.13, down 7.95% over 24 hours, with a bearish technical signal and recent earnings misses in three of the last four quarters. The company reported $1.2B revenue and $186.82M net income for 2025, with strong profitability margins but a negative net cash flow of $133.21M. A special dividend of $3.25 per share was declared, payable July 30, 2026, providing a near-term catalyst.
Outlook is mixed: strong fundamentals and dividend support value, but technical weakness and earnings misses signal caution. Risks include competitive pressures and consumer spending trends. Analyst consensus is cautious with 50% sell ratings. The stock presents a high-risk opportunity for dividend-focused investors amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
